Fox Chase Researcher Receives Award to Advance Small Cell Lung Cancer Research

PArth
Parth Desai, MBBS, MD, an assistant professor and medical oncologist at Fox Chase Cancer Center 

Parth Desai, MBBS, MD, an assistant professor and medical oncologist at Fox Chase Cancer Center, has received a $50,000 Binaytara Lung Cancer Research Award to advance research aimed at improving treatment selection for patients with small cell lung cancer.

Desai was selected as one of two recipients of the 2026 award.The recipients were announced Oct. 10 at the conclusion of the 2026 Seattle Lung Cancer Conference, organized by the global oncology nonprofit Binaytara.

Desai’s research project, titled “Tracking and Targeting Tumor-State Plasticity During DLL3 T-Cell Engager Therapy in Small Cell Lung Cancer,” focuses on developing a blood test that could help physicians determine which patients are most likely to benefit from an emerging immunotherapy.

Small cell lung cancer is an aggressive form of the disease. Although DLL3-targeted T-cell engager therapies have shown promise for patients whose cancer has returned following initial treatment, only about one-third of patients benefit. Currently, physicians lack reliable tools to predict which patients will respond.

Desai’s research aims to address this challenge by analyzing signals released by tumors into the bloodstream. This approach could help physicians identify patients most likely to benefit from treatment, detect early signs of treatment resistance and potentially reduce the need for repeated invasive biopsies.

 

The Binaytara-funded project builds on preliminary research supported by a Ride Hard Breathe Easy grant awarded in 2025. Insights from that earlier work helped shape the current proposal, which extends the investigation of tumor-state changes and blood-based markers of response and resistance during DLL3-targeted T-cell engager therapy.

Desai credited his mentors and colleagues at Fox Chase for their collaboration and support.

Hossein Borghaei, DO, MS, Chief of the Division of Thoracic Medical Oncology at Fox Chase, serves as Desai’s mentor and congratulated him on receiving the award.

The awards were determined through Binaytara’s Impact Pitch competition, which gives early-career investigators the opportunity to present research proposals to a panel of experienced oncology experts for live evaluation and feedback. The competition is designed to highlight promising research ideas and provide emerging investigators with resources to advance their work.

Both award recipients will return to present the progress and impact of their research at next year's Seattle Lung Cancer Conference.

The recognition provides support for Desai’s work to advance precision oncology approaches for small cell lung cancer, with the ultimate goal of helping physicians make more informed treatment decisions and improving care for patients facing this challenging disease.